PYC Therapeutics Statistics

Total Valuation

PYC Therapeutics has a market cap or net worth of AUD 676.58 million. The enterprise value is 611.38 million.

Market Cap	676.58M
Enterprise Value	611.38M

Important Dates

The last earnings date was Friday, November 29, 2024.

Earnings Date	Nov 29, 2024
Ex-Dividend Date	n/a

Share Statistics

PYC Therapeutics has 466.61 million shares outstanding. The number of shares has increased by 22.59% in one year.

Current Share Class	n/a
Shares Outstanding	466.61M
Shares Change (YoY)	+22.59%
Shares Change (QoQ)	+8.60%
Owned by Insiders (%)	42.43%
Owned by Institutions (%)	1.28%
Float	231.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	25.87
PB Ratio	8.41
P/TBV Ratio	8.85
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-16.21
EV / Sales	27.72
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-15.72

Financial Position

The company has a current ratio of 9.40, with a Debt / Equity ratio of 0.01.

Current Ratio	9.40
Quick Ratio	9.32
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.03
Interest Coverage	-789.64

Financial Efficiency

Return on equity (ROE) is -69.61% and return on invested capital (ROIC) is -43.79%.

Return on Equity (ROE)	-69.61%
Return on Assets (ROA)	-37.83%
Return on Capital (ROIC)	-43.79%
Revenue Per Employee	4.41M
Profits Per Employee	-7.55M
Employee Count	5
Asset Turnover	0.34
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +57.61% in the last 52 weeks. The beta is 0.71, so PYC Therapeutics's price volatility has been lower than the market average.

Beta (5Y)	0.71
52-Week Price Change	+57.61%
50-Day Moving Average	1.76
200-Day Moving Average	1.35
Relative Strength Index (RSI)	37.33
Average Volume (20 Days)	427,415

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PYC Therapeutics had revenue of AUD 22.06 million and -37.73 million in losses. Loss per share was -0.10.

Revenue	22.06M
Gross Profit	22.06M
Operating Income	-38.86M
Pretax Income	-38.11M
Net Income	-37.73M
EBITDA	-38.12M
EBIT	-38.86M
Loss Per Share	-0.10

Full Income Statement

Balance Sheet

The company has 66.87 million in cash and 1.11 million in debt, giving a net cash position of 65.76 million or 0.14 per share.

Cash & Cash Equivalents	66.87M
Total Debt	1.11M
Net Cash	65.76M
Net Cash Per Share	0.14
Equity (Book Value)	81.05M
Book Value Per Share	0.17
Working Capital	76.51M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -38.59 million and capital expenditures -307,044, giving a free cash flow of -38.90 million.

Operating Cash Flow	-38.59M
Capital Expenditures	-307,044
Free Cash Flow	-38.90M
FCF Per Share	-0.08

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -176.15% and -171.02%.

Gross Margin	100.00%
Operating Margin	-176.15%
Pretax Margin	-172.76%
Profit Margin	-171.02%
EBITDA Margin	-172.80%
EBIT Margin	-176.15%
FCF Margin	n/a

Dividends & Yields

PYC Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.59%
Shareholder Yield	-22.59%
Earnings Yield	-6.62%
FCF Yield	-5.75%

Stock Splits

The last stock split was on November 15, 2024. It was a reverse split with a ratio of 0.1.

Last Split Date	Nov 15, 2024
Split Type	Reverse
Split Ratio	0.1

Scores

PYC Therapeutics has an Altman Z-Score of 16.43.

Altman Z-Score	16.43
Piotroski F-Score	n/a